|Forbes.com, Spring, 2012. This article was placed on behalf of the U.S. based equity research effort of institutional broker and investment bank Canaccord Genuity. It was part of a series of articles developed under an agreement with forbes.com to work with a variety of contributors and assist them in delivering actionable investment ideas each week. The site, forbes.com is one of the top 500 sites in the world with nearly 10 million subscribers and approximately 100 million page views a month.|
Going into the Q1/12 earnings season for diabetes and wound care companies, Canaccord Genuity medical devices analyst William Plovanic noted his long term buys in the field were DexCom (DXCM : NASDAQ : $9.97 | BUY), Insulet (PODD : NASDAQ : $18.35 | BUY), Derma Sciences (DSCI : NASDAQ : $9.67 | BUY).
He said, “We believe improvements in the broader economy, with consumer confidence and unemployment levels improving, may offset typical seasonality and therefore DexCom and Insulet may experience strong Q1/12 results.”
He added, “Alternatively, the broader wound care market is relatively insulated to economic pressures due to the non-discretionary nature of chronic wounds, and Derma Sciences is well positioned due to its differentiated advanced wound care portfolio and new product cycle.”